(Q35174213)

6 August 2017

1 reference

title

Trandolapril: a newer angiotensin-converting enzyme inhibitor (English)

1 reference

6 August 2017

David R P Guay

1

1 reference

6 August 2017

publication date

1 March 2003

1 reference

6 August 2017

published in

Clinical Therapeutics

1 reference

6 August 2017

volume

25

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

713-775

1 reference

Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Influence of the nonsulfhydryl angiotensin-converting enzyme inhibitor trandolapril on lipid and carbohydrate metabolism related to exercise capacity in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Ocular and orbital blood flow in patients with essential hypertension treated with trandolapril

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Cardiac effects of trandolapril in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Ambulatory blood pressure and urinary albumin excretion in diabetic (non-insulin-dependent and insulin-dependent) hypertensive patients: relationships at baseline and after treatment by the angiotensin converting enzyme inhibitor trandolapril

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Verapamil SR/trandolapril combination therapy for the elderly hypertensive patient. German VeraTran Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Antihypertensive efficacy of a once a day verapamil SR/trandolapril combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Once-daily trandolapril compared with the twice-daily formulation in the treatment of mild to moderate essential hypertension: assessment by conventional and ambulatory blood pressures.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Effects of the converting enzyme inhibitor trandolapril on short-term variability of blood pressure in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring. The Italian Trandolapril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Permanent Blood Pressure Control Over the 24 h by Trandolapril

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: the Veratran Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Trandolapril restores circadian blood pressure variation in normoalbuminuric normotensive Type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Failure of an ACE inhibitor to improve exercise tolerance. A randomized study of trandolapril. Trandolapril study group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

The TRAndolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. The Trace Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Ramipril: a review of its use in the prevention of cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Safety profile of the combination of verapamil and trandolapril

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

Calcium-antagonist drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980107-8

7 January 2021

10.1016/S0149-2918(03)80107-8

Identifiers

DOI

1 reference

6 August 2017

1 reference